Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL21145176 | 1.00 | TP53 (0.39) | TP53SLC7A5FFAR3LCKFYN | |
| Pyruvate SCHEMBL21145289 | 0.87 | TSHR (0.35) | TP53FFAR3LCKFYN | |
| Acetic Acid SCHEMBL21145178 | 0.86 | FFAR3 (0.50) | TP53SLC7A5FFAR3LCKFYN | |
| Hydrogen Peroxide SCHEMBL135349 | 0.84 | ALDH1A1 (0.33) | TP53 | |
| Hydrogen Peroxide SCHEMBL135351 | 0.84 | ALDH1A1 (0.33) | TP53 | |
| Lactic Acid SCHEMBL21145264 | 0.80 | TP53 (0.69) | TP53SLC7A5 | |
| Cadaverine Tartrate SCHEMBL21145056 | 0.78 | TSHR (0.59) | TP53SLC7A5 | |
| Propionic Acid SCHEMBL21145096 | 0.78 | FFAR3 (0.59) | TP53FFAR3 | |
| Cadaverine Tartrate SCHEMBL21145055 | 0.78 | TSHR (0.59) | TP53SLC7A5 | |
| Fumaric Acid SCHEMBL21145316 | 0.78 | TSHR (0.53) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200179254-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | HENKEL AG & CO. KGAA (DE) | 2020-06-11 | — | — | US | disclosed |
| US-20190240129-A1 | CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | HENKEL AG & CO. KGAA (DE) | 2019-08-08 | — | — | US | disclosed |
| EP-3518878-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | Henkel AG & Co. KGaA (DE) | 2019-08-07 | — | — | EP | disclosed |
| US-20190216703-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | HENKEL AG & CO. KGAA (DE) | 2019-07-18 | — | — | US | disclosed |
| US-20190216714-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | HENKEL AG & CO. KGAA (DE) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240129-A1 | CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | KRT18, CUTA, S100A10 | TP53 2105/4885SLC7A5 1580/4885FFAR3 2270/4885 |
| US-20190216703-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | KRT18, SRRM2, IK | TP53 2548/4885SLC7A5 1746/4885FFAR3 1837/4885 |
| US-20190216714-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | KRT18, CD44, PCNA | TP53 1209/4885SLC7A5 662/4885FFAR3 3218/4885 |
| US-20200179254-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | KRT18, CUTA, DSG1 | TP53 1442/4885SLC7A5 892/4885FFAR3 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.